Evaluation of recurrence in localized and metastatic prostate cancer
For patients with localized prostate cancer, after radical prostatectomy, two consecutive serum PSA values higher than 0.2 ng/mL and/or increment were defined as biochemical recurrence (BCR). Currently, BCR has been accepted as the first rise (≥0.2ng/mL) in PSA25.
For patients with metastatic prostate cancer, castration resistance prostate cancer (CRPC) accepted for recurrence. CRPC is defined as castrating serum testosterone <50 ng/dl or 1.7 nmol/l plus one of the following types of progression.
Biochemical progression: Three consecutive rises in PSA 1 week apart, resulting in two 50% increases over the nadir, and PSA > 2 ng/ml.
Radiologic progression: The appearance of new lesions: either two or more new bone lesions on bone scan or a soft tissue lesion using the Response Evaluation Criteria in Solid Tumours (RECIST)26,27.